Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Metabolically Healthy Obesity

Open access
Blüher, Matthias · 2020 · Endocrine Reviews

Abstract

Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endrev/bnaa004

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1. Phenotypic traits associated with metabolically healthy versus unhealthy obesity. Individuals with metabolically healthy obesity (MHO, prevalence ~10–30%) are characterized by lower liver and visceral fat mass, higher leg fat content, greater cardiorespiratory fitness and physical activity, insulin sensitivity, normal inflammation markers, and preserved adipose tissue function compared to patients with metabolically unhealthy obesity (MUO, prevalence ~80–90%). Transabdominal MRI scans with highlighted (yellow) visceral fat depot area from 2 women with the same age and BMI, but either MHO or MUO show ~2.6-fold higher visceral fat deposition associated with MUO (pictures provided by Nicolas Linder).
Figure 1. Phenotypic traits associated with metabolically healthy versus unhealthy obesity. Individuals with metabolically healthy obesity (MHO, prevalence ~10–30%) are characterized by lower liver and visceral fat mass, higher leg fat content, greater cardiorespiratory fitness and physical activity, insulin sensitivity, normal inflammation markers, and preserved adipose tissue function compared to patients with metabolically unhealthy obesity (MUO, prevalence ~80–90%). Transabdominal MRI scans with highlighted (yellow) visceral fat depot area from 2 women with the same age and BMI, but either MHO or MUO show ~2.6-fold higher visceral fat deposition associated with MUO (pictures provided by Nicolas Linder).CC BY · PubMed Central
Figure 2. Metabolically healthy obesity is a transient phenotype. Case example for a 48-year-old man undergoing different weight-loss interventions. At baseline, the patient presented with MUO as defined by reference (31). After 12 months of a behavior intervention program (calorie restricted diet, increased physical activity, and psychosocial support), the phenotype changed into MHO. Because treatment was not continued for the subsequent 12 months, there was a weight regain associated with a phenotype transition to MUO. At 24 months, the patient underwent a laparoscopic Roux-en-Y gastric bypass surgery, which resulted in significant weight loss and improvements in all criteria defining MHO. The case demonstrates that transitions between MUO and MHO are not unidirectional and may change over time, for instance in response to weight-loss interventions. Abbreviations: BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.
Figure 2. Metabolically healthy obesity is a transient phenotype. Case example for a 48-year-old man undergoing different weight-loss interventions. At baseline, the patient presented with MUO as defined by reference (31). After 12 months of a behavior intervention program (calorie restricted diet, increased physical activity, and psychosocial support), the phenotype changed into MHO. Because treatment was not continued for the subsequent 12 months, there was a weight regain associated with a phenotype transition to MUO. At 24 months, the patient underwent a laparoscopic Roux-en-Y gastric bypass surgery, which resulted in significant weight loss and improvements in all criteria defining MHO. The case demonstrates that transitions between MUO and MHO are not unidirectional and may change over time, for instance in response to weight-loss interventions. Abbreviations: BMI, body mass index; BP, blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; TG, triglycerides.CC BY · PubMed Central
Figure 3. Adipose tissue dysfunction and development of metabolically unhealthy obesity. A chronically positive energy balance requires expansion of adipose tissue (AT) to store excess energy. Adipose tissue responds to higher storage demands by increasing the adipocyte number through adipogenesis from precursor cells (hyperplasia) and through adipocyte hypertrophy. If expansion of healthy fat stores (eg, subcutaneous leg fat) and the ability of AT to respond to excess calorie intake with (“healthier”) hyperplasia are impaired, AT dysfunction may develop, which is characterized by ectopic fat deposition (eg, liver, abdominal visceral depots, skeletal muscle, pancreas) and a sequence from adipocyte hypertrophy, hypoxia, inadequate vascularization, AT stress, and immune cell infiltration, apoptosis, and increased production of profibrotic extracellular matrix proteins contributing to fibrosis. Adipose tissue dysfunction leads to the release of proinflammatory, diabetogenic, and atherogenic signals (eg, adipokines, fatty acids from increased lipolysis, other metabolites, immune cells), which may contribute to end organ damage (eg, liver, skeletal muscle, pancreas, vasculature) and the development of metabolically unhealthy obesity. In contrast, healthy expansion of AT leads to metabolically healthy obesity through an increased AT storage capacity (serving as a safe “metabolic sink”) and the secretion of a beneficial adipokine profile (eg, adiponectin, FGF-21, leptin) (adapted from references (60, 61).
Figure 3. Adipose tissue dysfunction and development of metabolically unhealthy obesity. A chronically positive energy balance requires expansion of adipose tissue (AT) to store excess energy. Adipose tissue responds to higher storage demands by increasing the adipocyte number through adipogenesis from precursor cells (hyperplasia) and through adipocyte hypertrophy. If expansion of healthy fat stores (eg, subcutaneous leg fat) and the ability of AT to respond to excess calorie intake with (“healthier”) hyperplasia are impaired, AT dysfunction may develop, which is characterized by ectopic fat deposition (eg, liver, abdominal visceral depots, skeletal muscle, pancreas) and a sequence from adipocyte hypertrophy, hypoxia, inadequate vascularization, AT stress, and immune cell infiltration, apoptosis, and increased production of profibrotic extracellular matrix proteins contributing to fibrosis. Adipose tissue dysfunction leads to the release of proinflammatory, diabetogenic, and atherogenic signals (eg, adipokines, fatty acids from increased lipolysis, other metabolites, immune cells), which may contribute to end organ damage (eg, liver, skeletal muscle, pancreas, vasculature) and the development of metabolically unhealthy obesity. In contrast, healthy expansion of AT leads to metabolically healthy obesity through an increased AT storage capacity (serving as a safe “metabolic sink”) and the secretion of a beneficial adipokine profile (eg, adiponectin, FGF-21, leptin) (adapted from references (60, 61).CC BY · PubMed Central
Figure 4. Risk of CVD and cardiovascular events, type 2 diabetes (T2D), and all-cause and/or CVD event mortality in MHO. Metabolically healthy lean (MHL) served as a reference group, and the mean relative risk for incident diseases, events, or mortality was compared between the MHO group (defined as absence of any metabolic abnormalities) and a group of individuals with MUO. Data are extracted from previous meta-analyses (34, 79, 80) or a large recent cohort study (43). For data from reference (44), only the subgroup of MUO with 3 metabolic comorbidities (= highest relative risk) is displayed despite evidence for gradually increasing risk (in all categories) with the increased number of metabolic abnormalities (ranging from 1–3).
Figure 4. Risk of CVD and cardiovascular events, type 2 diabetes (T2D), and all-cause and/or CVD event mortality in MHO. Metabolically healthy lean (MHL) served as a reference group, and the mean relative risk for incident diseases, events, or mortality was compared between the MHO group (defined as absence of any metabolic abnormalities) and a group of individuals with MUO. Data are extracted from previous meta-analyses (34, 79, 80) or a large recent cohort study (43). For data from reference (44), only the subgroup of MUO with 3 metabolic comorbidities (= highest relative risk) is displayed despite evidence for gradually increasing risk (in all categories) with the increased number of metabolic abnormalities (ranging from 1–3).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 123 references

Cited by

See all 1,090

Metadata

Authors
Blüher, M.
Affiliations
Helmholtz Munich (DE)
Corresponding author
Blüher, Matthias
Venue
Endocrine Reviews
Published
2020-03-04
Volume
41
Issue
3
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W3009496837
Cited by
1,090
References
123
Citations by year
2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
FWCI
86.17
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Site cant be reached (submittedVersion, cc-by)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
Deutsche Forschungsgemeinschaft (209933838)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
MeSH terms
Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolically Healthy Obesity. https://app.cochat.ai/papers/10.1210/endrev/bnaa004
The paper
Blüher, M. (2020). Metabolically Healthy Obesity. Endocrine Reviews. https://doi.org/10.1210/endrev/bnaa004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.